SECONDARY ACUTE MYELOID LEUKEMIA
Clinical trials for SECONDARY ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new SECONDARY ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for SECONDARY ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early trial aims to boost immune system to fight tough blood cancers
Disease control OngoingThis early-stage study is testing the safety and best dose of a two-drug combination for people with aggressive forms of blood cancer (myelodysplastic syndrome or acute myeloid leukemia) that have returned or not responded to prior treatments. The trial combines a chemotherapy dr…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for Tough-to-Treat leukemia: experimental drug combo enters testing
Disease control TerminatedThis study is testing whether adding a drug called venetoclax to a standard chemotherapy regimen (FLAG or CLAG) is more effective for treating newly diagnosed secondary acute myeloid leukemia (sAML). The main goal is to see if this combination helps more patients achieve complete…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New drug combo tested to fight leukemia in seniors
Disease control OngoingThis study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, to treat older adults with a type of blood cancer called acute myeloid leukemia (AML). The goal was to see if this combination was safe and effective enough to put patients into remission and war…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Scientists test Triple-Threat attack on tough blood cancer
Disease control OngoingThis early-stage study is testing a new combination of three drugs—navtemadlin, decitabine, and venetoclax—for adults with acute myeloid leukemia (AML) that has returned, is resistant to treatment, or is newly diagnosed in patients who cannot tolerate intensive chemotherapy. The …
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Immune-Boosting drug joins fight against tough blood cancer in seniors
Disease control OngoingThis study is testing if adding an immunotherapy drug (pembrolizumab) to a standard two-drug combination works better for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemotherapy. The goal is to see if the three-drug combo helps more p…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New antibody drug enters human testing for Tough-to-Treat blood cancers
Disease control OngoingThis is a first-in-human study to find a safe dose of an experimental antibody drug called Hu8F4 for patients with advanced blood cancers like leukemia and myelodysplastic syndrome (MDS). The main goals are to check for side effects and see how the body processes the drug. The st…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New radiation technique tested to improve stem cell transplants for tough blood cancers
Disease control TerminatedThis early-stage study aims to find the safest and most effective dose of a targeted radiation treatment, given with chemotherapy, to prepare patients for a donor stem cell transplant. It is for people with high-risk forms of acute leukemia or myelodysplastic syndrome who are not…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
New hope for AML patients: can a Cancer-Fighting drug boost Chemo's power?
Disease control OngoingThis study is testing if adding the immunotherapy drug pembrolizumab to standard chemotherapy works better for adults newly diagnosed with acute myeloid leukemia (AML). The goal is to see if the combination helps more patients achieve a deep remission with no detectable cancer ce…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
New hope for tough leukemia in younger patients
Disease control OngoingThis study is testing how well a chemotherapy drug called CPX-351 works for adults under 60 with secondary acute myeloid leukemia, a type of blood cancer that develops from other blood disorders or previous cancer treatments. The goal is to see if this drug can help patients achi…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 23, 2026 15:15 UTC
-
Scientists Re-Engineer Patient's own cells to hunt down leukemia
Disease control OngoingThis early-stage study is testing a new type of cellular therapy for adults with acute myeloid leukemia or a related blood cancer that has come back or not responded to standard treatments. Doctors collect a patient's or donor's immune cells, genetically modify them in a lab to b…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 16, 2026 15:27 UTC
-
New strategy aims to tame dangerous virus after cancer transplant
Disease control OngoingThis study is testing a personalized plan to manage cytomegalovirus (CMV), a common and potentially serious infection, in patients who have received a donor stem cell transplant for blood cancers or disorders. The plan involves closely monitoring the virus level and the patient's…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 16, 2026 15:26 UTC
-
New strategy aims to make leukemia cells more vulnerable to chemo
Disease control OngoingThis study is testing whether adding a drug called decitabine before standard chemotherapy helps treat acute myeloid leukemia (AML) more effectively. The goal is to see if decitabine can 'prime' or sensitize the cancer cells, making them easier for the chemotherapy drugs to kill.…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 11, 2026 14:54 UTC
-
Scientists test new drug cocktail in fight against tough blood cancer
Disease control OngoingThis early-stage study is testing a combination of three drugs—bortezomib, sorafenib, and decitabine—to treat acute myeloid leukemia (AML). The main goal is to find the safest and most effective dose. The study is for adults with AML who are older, have a type that is hard to tre…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 02, 2026 15:24 UTC
-
Phone therapy trial aims to ease debilitating cancer fatigue
Symptom relief OngoingThis study is testing whether a type of talk therapy, delivered over the phone, can help patients with acute myeloid leukemia (AML) or lymphoma manage severe, long-lasting cancer-related fatigue. The therapy focuses on teaching patients skills to change unhelpful thoughts and beh…
Matched conditions: SECONDARY ACUTE MYELOID LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Mar 12, 2026 13:50 UTC